The comparison of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility
Background and aim: Luteal phase supplementation allows programming of treatment cycles in this trial we compared the effect of GnRH agonist administration with vaginal progesterone on serum progesterone in luteal phase in control ovarian hyperstimulation and intrauterine insemination cycles. Methods and materials: In this clinical trial 242 patients with UEI (unexplained infertility) candidate for ovarian stimulation and intrauterine insemination referring to infertility ward of Mirza khuchak khan Hospital were recruited. The patients were randomized into two groups (group A or Progesterone group) and (B or GnRH agonist group).The luteal phase was routinely supplemented in 121 patients (group A) with 400mg/day/vaginally of natural micronized progesterone starting 1 days after the IUI (intrauterine insemination) for two weeks. In B group (121 patients) a single dose of GnRH agonist (triptorelin 0.1mg) subcutaneously was injected 4 days after IUI. Then serum progesterone level was compared 10 days after IUI in two groups. Results: Totally we evaluated 240 patients with mean age 28.42±4.02 (20-38). The mean serum level progesterone in A group was 33.45±18.12ng/ml and in B group was 32.50±23.82ng/ml and the difference between two groups was not significant (p=0.72). Also, regarding results of IUI, we found BHCG positive in 20 patients in vaginal group and 19 patients in GnRH group (p=0.86). Moreover, clinical pregnancy was detected in 15 patients in vaginal progesterone group and in 15 patients in GnRH group (p=NS). Conclusion; the GnRH agonist showed comparable effect with vaginal progesterone on luteal phase supporting in patients with unexplained infertility.